Domů › Rakovina prostaty › Ohio › Cleveland
Klinické studie Rakovina prostaty v Cleveland, OH
34 studií pro Rakovina prostaty hledá účastníky v lokalitách v Cleveland a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Probíhá náborFáze 1/2
- The Cleveland Clinic Taussig Cancer Center, Cleveland
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Probíhá náborFáze 3
- MetroHealth Medical Center, Cleveland
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Probíhá náborFáze 1
- University Hospitals Cleveland Medical Center, Cleveland
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Probíhá náborFáze 2
- MetroHealth Medical Center, Cleveland
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
Probíhá náborFáze 2
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Cente, Cleveland
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Probíhá nábor
- University Hospitals Cleveland Medical Center, Cleveland
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Probíhá náborFáze 1
- University Hospitals Cleveland Medical Center, Cleveland
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Probíhá náborFáze 3
- University Hospitals Cleveland Medical Center ( Site 0043), Cleveland
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Probíhá náborFáze 1
- University Hospitals Cleveland Medical Center, Cleveland
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Probíhá náborFáze 3
- University Hospitals Cleveland Medical Center, Cleveland
- UH Minoff Health Center at Chagrin Highlands, Orange · Vzdálenost 12 mi
- University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor · Vzdálenost 22 mi
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Probíhá náborFáze 2
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
Investigation of Impact of AI on Prostate Cancer Workflow
Probíhá nábor
- Cleveland Clinic Foundation, Cleveland
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Probíhá nábor
- University Hospitals Cleveland, Cleveland
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Probíhá náborFáze 3
- Case Western Reserve University, Cleveland
- Louis Stokes Cleveland VA Medical Center, Cleveland
- MetroHealth Medical Center, Cleveland
- a dalších 5
The Vanguard Study: Testing a New Way to Screen for Cancer
Probíhá náborVítáni zdraví dobrovolníci
- Louis Stokes Cleveland VA Medical Center, Cleveland
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Probíhá náborFáze 3
- Research Site, Cleveland
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Probíhá náborFáze 2
- University Hospitals Cleveland Medical Center, Cleveland
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1/2
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Probíhá nábor
- Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Probíhá náborFáze 3
- Case Western Reserve University, Cleveland
- MetroHealth Medical Center, Cleveland
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- a dalších 5
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
Probíhá náborObservační studie
- Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company, Cleveland
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Probíhá náborFáze 1
- Cleveland Clinic Foundation, Cleveland
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Probíhá náborFáze 4
- Cleveland Clinic Foundation, Cleveland
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
Probíhá náborFáze 1/2
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Probíhá náborObservační studie
- University Hospitals Cleveland Medical Center, Cleveland
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Probíhá náborFáze 1
- Research Site, Cleveland
Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
Probíhá nábor
- UH Cleveland Medical Center, Cleveland
Cleveland African American Prostate Cancer Project
Probíhá náborVítáni zdraví dobrovolníci
- Barbershops Local to Cleveland, Cleveland
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Probíhá náborFáze 2/3
- Louis Stokes VA Medical Center, Cleveland, OH, Cleveland
Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer
Probíhá nábor
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- Cleveland Clinic, Cleveland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Probíhá náborObservační studie
- Massive Bio SYNERGY-AI site, Mayfield Heights · Vzdálenost 12 mi
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Probíhá náborFáze 3
- MetroHealth Medical Center, Cleveland
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Probíhá náborFáze 1
- Exelixis Clinical Site #7, Cleveland
Studie Rakovina prostaty v jiných městech
- New York City, NY103 studií
- Houston, TX76 studií
- Los Angeles, CA61 studií
- Boston, MA59 studií
- St. Louis, MO46 studií
- Chicago, IL45 studií
- San Francisco, CA45 studií
- Philadelphia, PA44 studií
- Baltimore, MD43 studií
- Nashville, TN42 studií
- Seattle, WA42 studií
- Washington, DC38 studií
Další studie v Cleveland
- Nemalobuněčný plicní karcinom43 studií
- Rakovina (všechny typy)36 studií
- Rakovina prsu35 studií
- Srdeční selhání33 studií
- Metastatický karcinom30 studií
- Rakovina vaječníků30 studií
- Rakovina plic26 studií
- Kolorektální karcinom24 studií
- Kardiovaskulární onemocnění22 studií
- Rakovina endometria20 studií
- Akutní myeloidní leukemie20 studií
- Crohnova choroba19 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.